Early access
Sign in
Not yet recruitingPhase 1

Testing CNTX-0066 injection for long-lasting knee osteoarthritis pain

Tests a single CNTX-0066 knee injection in adults with painful knee osteoarthritis.

Key facts

Who runs it
Centrexion Therapeutics Corp.
Where
Denmark1 site in 1 countryChoose a country to see its sites
Registry title
A Pilot, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of a Single Intra-articular Injection of CNTX-0066 in Participants with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain
Status
Not yet recruiting
Phase
Phase 1
People taking part
20 people, planned
Started
23 Mar 2026
Planned end
11 Nov 2026
Type of study
Interventional
Record updated
24 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with long-lasting, moderate-to-severe knee pain from osteoarthritis. Participants get one injection of CNTX-0066 or a placebo into the knee joint.

Age
18 Years and older
Sex
All sexes can join
Disease stage
Chronic, moderate-to-severe osteoarthritis knee pain

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Testing CNTX-0066 injection for long-lasting knee osteoarthritis painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
24 February 2026